top of page
CNTA/ALKS/Takeda: Differentiation challenges for ORX750 orexin agonist vs Takeda in NT1&2, despite clean phase 1
Threading the narrowing orexin needle
Ahead of CNTA’s ORX750 phase 2 data, our in-depth orexin agonist analysis highlights several difficulties in demonstrating differentiation to Takeda’s TAK861, besides once a day as likely second to market in NT1, as well as unclear prospects in the naïve NT2 market.
bottom of page